Integration of serum metabolomics and network pharmacology reveals the immunoenhancing mechanisms of Qishenbuqi capsules
Toxicology Research · 24.04.2023 · 12 (2) · 201-215
DOI: 10.1093/toxres/tfad008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicology Research, online erschienen am 14.02.2023. Verfasst von Ziyu Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan 030006, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Epidemic Special Project of Shanxi Provincial Education Department, Key Laboratory of Effective Substances Research and Utilization in TCM of Shanxi Province.
Abstract (Originalsprache)
Introduction
Qishenbuqi capsule (QSBQC), a listed Chinese patent prescription, comprises of 4 herbs. Clinically, it has been shown to improve immune functions.
Methods
Subjects with Qi deficiency and non-Qi deficiency were recruited, who then took QSBQC for 4 weeks. Traditional Chinese medicine (TCM) syndrome scores and the levels of white blood cells, CD3+ T cells (CD3+), CD4+ T cells (CD3+CD4+), CD8+ T cells (CD3+CD8+), and CD4+/CD8+ were determined. Serum metabolomics was used to explore the metabolic mechanisms of QSBQC on improving immunity. Meanwhile, the potential active ingredients, targets, and pathways of QSBQC on enhancing immunity were screened by network pharmacology.
Results
QSBQC significantly improved TCM syndrome scores and increased the number of CD8+ T cells of both Qi deficiency and non-Qi deficiency subjects. Serum metabolomics revealed that QSBQC regulated 18 differential metabolites and 8 metabolic pathways of Qi deficiency, and 12 differential metabolites and 7 metabolic pathways of non-Qi deficiency subjects. The “herbs-compounds-pathways” diagram showed that PQ-2, cimifugin, and divaricatol were the main active components. Pathways in cancer and arginine and proline metabolism could be the most important pathways.
Conclusion
Our research revealed the immunoenhancing mechanisms of QSBQC and improved the combination of TCM theory and modern western medicine theory.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan 030006, China.
- Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, Taiyuan 030006, China.
- Key Laboratory of Effective Substances Research and Utilization in TCM of Shanxi Province, Taiyuan 030006, China.
- The First Hospital of Shanxi Medical University, Taiyuan 030001, China.
- The Center for Disease Control and Prevention of Taiyuan, Taiyuan 030012, China.
- Taiyuan Jinyuan District Center for Disease Control and Prevention, Taiyuan 030000, China.
ORCID-Profile: Xuemei Qin
Förderung
- Epidemic Special Project of Shanxi Provincial Education Department
- Key Laboratory of Effective Substances Research and Utilization in TCM of Shanxi Province
Zitieren
APA
Zhao, Z., Fan, Y., Cui, Y., Yang, L., Wu, Y., Yuan, Y., Zhang, P., Zhao, R., Ji, J., Xu, S., Qin, X., & Liu, X. J. (2023). Integration of serum metabolomics and network pharmacology reveals the immunoenhancing mechanisms of Qishenbuqi capsules. Toxicology Research, 12(2), 201-215. https://doi.org/10.1093/toxres/tfad008
Vancouver
Zhao Z, Fan Y, Cui Y, Yang L, Wu Y, Yuan Y, et al. Integration of serum metabolomics and network pharmacology reveals the immunoenhancing mechanisms of Qishenbuqi capsules. Toxicology Research. 2023;12(2):201-215. doi:10.1093/toxres/tfad008
BibTeX
@article{Zhao2023,
author = {Zhao, Ziyu and Fan, Yuhui and Cui, Yutao and Yang, Lan and Wu, Yanfei and Yuan, Yuan and Zhang, Ping and Zhao, Ruping and Ji, Jianjun and Xu, Sheng and Qin, Xuemei and Liu, Xiao-Jie},
title = {Integration of serum metabolomics and network pharmacology reveals the immunoenhancing mechanisms of Qishenbuqi capsules},
journal = {Toxicology Research},
year = {2023},
volume = {12},
number = {2},
pages = {201--215},
doi = {10.1093/toxres/tfad008}
}
EUVIMED